Spectrum Therapeutics Announces Donation to Support Research and Education Initiatives led by the Canadian Sleep and Circadian Network

SMITHS FALLS, ON and MONTREAL, QC – Spectrum Therapeutics (“Spectrum”), the medical division of Canopy Growth Corporation (TSX: WEED) (NYSE: CGC) is pleased to announce a donation to the Fondation de l’Hôpital du Sacré-Coeur de Montreal (Montreal Sacre Coeur Hospital Foundation) to support the Canadian Sleep and Circadian Network’s (“CSCN”) associated national campaign: Sleep On It which aims to raise awareness about the importance of good quality sleep on health. 

Spectrum’s donation to the campaign has been made, based on CSCN’s request to support their initiative to organize the sleep scientific community around the question of cannabis use for sleep disorders. Although an increasing volume of anecdotal data indicates the growing usage of cannabis from individuals coping with sleep disorders, clinical scientific evidence on its effectiveness is still limited. Hence, via this donation, CSCN will be able to provide to the public, health management decision makers as well as the sleep scientific community, a review of currently available data and identify the research gaps that need to be filled. This review is expected to be completed during the second half of the 2020 calendar year.  

By partnering with the leader in the cannabis industry, CSCN’s objective is to combine the expertise of clinicians, physicians and researchers across the country to facilitate and scientifically support the development of a white paper based on a comprehensive review of all existing literature and facts about the use of cannabis in sleep disorder management. The report is also expected to be published during the second half of the 2020 calendar year and will introduce an updated clinical research program looking at all areas that impact quality of sleep, including pain, aging, and sleep disorders such as insomnia. Ultimately, the white paper will provide insights and guidance on future research directions and further requirements for evidence on the potential application of medical cannabis in treating sleep disorders.

“Good quality sleep is far more important to our long-term health than most people realize,” commented Dr. Mark Ware, Chief Medical Officer, Canopy Growth. “We’re just now beginning to explore the role cannabis can play in addressing sleep-related disorders. Patient feedback is very promising so far, and partnerships such as these will advance our understanding of the intriguing phenomenon of sleep that is so essential to our overall well-being.” 

The legalization of cannabis in Canada has brought about a natural interest in the potential for cannabis in the treatment of sleeping disorders. We need to catalyze the development of collective efforts to further develop scientific knowledge platforms to inform policy, therapeutic practice, and prevention efforts about sleep and cannabis and to scientifically inform decision makers as well as general public about the research needs to produce evidence based data on sleep and cannabis,” commented Dr Julie Carrier, Scientific director of the Canadian Sleep & Circadian Network and sleep researcher at the CIUSSS du Nord-de-l’Île-de-Montreal.

One in three Canadians don’t get the recommended seven hours of sleep each night. The CSCN’s mission is to mobilize the healthcare community to adopt an integrated approach towards improving outcomes and treatment of patients with sleep disorders. 

Here’s to Future Growth (and better sleep!)


Canopy Growth
Carly Pickett
Media Relations

Tyler Burns
Investor Relations
855-558-9333 ex 122

Centre intégré universitaire de santé et de services sociaux du Nord-de-l’Île-de-Montréal (CIUSSS du Nord-de-l’île-de-Montréal)
Emilie Jacob
Medias relations and public affairs office
Centre intégré universitaire de santé et de services sociaux du Nord-de-l’Île-de-Montréal

Montreal Hospital Sacré-Coeur Foundation
Paul Bergeron
Chief Executive Officer
514 338-2303, poste 8